Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB, commonly known as Sobi, is a leading biopharmaceutical company headquartered in Sweden (SE). Founded in 1991, Sobi has established itself as a key player in the biotechnology industry, focusing on rare diseases and specialty care. With a strong operational presence across Europe, North America, and the Asia-Pacific region, Sobi is dedicated to developing innovative therapies that address unmet medical needs. Sobi's core product portfolio includes treatments for haemophilia, inflammation, and genetic disorders, distinguished by their commitment to patient-centric solutions and advanced biopharmaceutical technologies. The company has achieved significant milestones, including strategic partnerships and a robust pipeline of therapies, solidifying its market position as a trusted provider in the rare disease sector. Sobi continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by complex health conditions.
DitchCarbon Score
How does Swedish Orphan Biovitrum's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Swedish Orphan Biovitrum's score of 32 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Swedish Orphan Biovitrum's reported carbon emissions
In 2023, Swedish Orphan Biovitrum (Sobi) reported total carbon emissions of approximately 124,565,000 kg CO2e. This figure includes 904,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 648,000 kg CO2e from Scope 2 emissions, related to the generation of purchased electricity, steam, heating, and cooling. The majority of their emissions, approximately 124,565,000 kg CO2e, fall under Scope 3, which includes indirect emissions from the value chain, such as business travel and purchased goods and services. Over the years, Sobi has seen fluctuations in its total emissions, with a peak of approximately 5,215,000 kg CO2e in 2021. Notably, their Scope 1 and 2 emissions combined totalled about 1,551,000 kg CO2e in 2023, reflecting a commitment to monitoring and managing their carbon footprint. Despite the absence of specific reduction targets or initiatives disclosed, Sobi's emissions data indicates a focus on transparency and accountability in their climate impact. The company continues to engage in practices that align with industry standards for emissions reporting, although further details on specific climate commitments or reduction strategies are not available.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 435,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 1,157,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 1,031,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Swedish Orphan Biovitrum is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
